Company intelligence / Profile preview
EyeGene, Inc.
Seoul or Incheon area likely—zip code '07528' referenced, South Koreaeyegene.co.kr ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
EyeGene has several clinical-stage programs including an mRNA COVID‑19 vaccine in Phase I/IIa trials in Korea and Australia; a herpes zoster vaccine that completed Phase I in Australia; EG-Mirotin for diabetic retinopathy that completed Phase IIa in the EU and Korea; EG-myocin for myocardial ischemia/reperfusion injury currently in Phase II trial. The company also has a VLP-based HPV vaccine that finished a domestic Phase I trial. Some assets have been licensed domestically to Huons[2].
- Therapeutic areas
- OphthalmologyCardiovascularInfectious Diseases
- Modalities
- mRNA vaccinesRecombinant proteins (including growth factors and decorin)Virus-like particles (VLPs)Proprietary immune adjuvants
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →03
Partnerships
Domestic licensing partnership with Huons for EG-decorin. Seeking global licensing partners for multiple assets including EG-Mirotin, EG-myocin, and their vaccines[2].
Beyond the preview
Go deeper on EyeGene, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EyeGene, Inc..